. . "Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. "@en . . . "Alogliptin is 20% bound to plasma proteins."@en . "The pharmacokinetics of NESINA was also shown to be similar in healthy subjects and in patients with type 2 diabetes. When single, oral doses up to 800 mg in healthy subjects and type 2 diabetes patients are given, the peak plasma alogliptin concentration (median Tmax) occurred 1 to 2 hours after dosing. Accumulation of aloglipin is minimal. The absolute bioavailability of NESINA is approximately 100%. Food does not affect the absorption of alogliptin. "@en . "Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues."@en . . . . . . . "Kenji Nakamura, Kenichiro Kiyoshima, Junya Nomura, \"SOLID PREPARATION COMPRISING ALOGLIPTIN AND PIOGLITAZONE.\" U.S. Patent US20100092551, issued April 15, 2010."@en . . "SYR-322"@en . . " "@en . . . . "Renal clearance = 9.6 L/h (this value indicates some active renal tubular secretion); Systemic clearance = 14.0 L/h. "@en . "850649-61-5"@en . . . . . . . . "Common adverse reactions (reported in \u22654% of patients treated with alogliptin 25 mg and more frequently than in patients who received placebo) are: nasopharyngitis, headache, and upper respiratory tract infection. "@en . . . "Renal excretion (76%) and feces (13%). 60% to 71% of the dose is excreted as unchanged drug in the urine."@en . . . "Alogliptinum"@en . . . . "approved"@en . . . . . . . . . . . "Terminal half-life = 21 hours "@en . . . . . . " "@en . "Alogliptina"@en . . . . . . . . "Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013. "@en . . . . . . "Alogliptin"@en . "Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying."@en . "Alogliptine"@en . "# Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008 Mar;30(3):513-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18405789 # Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008 Mar;30(3):499-512. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18405788 # FDA label # Golightly LK, Drayna CC, McDermott MT: Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14. doi: 10.2165/11632930-000000000-00000. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/22686547"@en . "Humans and other mammals"@en .